摘要
目的:分析早期应用孟鲁司特钠在预防儿童肺炎支原体感染后喘息发作的可行性。方法:选取笔者所在医院2018年1月-2019年1月收治的175例确诊为肺炎支原体感染而尚未出现喘息发作的儿童,按照随机数字表法分为对照组和观察组,对照组87例,观察组88例。对照组采用常规阿奇霉素治疗,观察组在对照组基础上联合孟鲁司特钠进行治疗。观察两组临床疗效、临床症状及C反应蛋白水平。结果:观察组治疗总有效率(92.05%)高于对照组(74.71%),差异有统计学意义(P<0.05)。观察组咳嗽消失时间、啰音消失时间均早于对照组,喘息次数少于对照组,差异均有统计学意义(P<0.05)。治疗前两组C反应蛋白水平比较差异无统计学意义(P>0.05),治疗1周、1个月后,观察组均低于对照组,差异均有统计学意义(P<0.05)。结论:早期应用孟鲁司特钠在预防儿童肺炎支原体感染后喘息发作中具有较高的可行性,可提高患儿的临床疗效,减少咳嗽时间与喘息次数,阻断炎症反应,值得临床推广。
Objective:To analyze the feasibility of early application of Montelukast Sodium in the prevention of wheezing attack after mycoplasma pneumoniae infection in children.Method:From January 2018 to January 2019,175 children who had been diagnosed with mycoplasma pneumoniae infection but had no wheezing attack were divided into the control group and the observation group according to the random number table method,87 cases in the control group and 88 cases in the observation group.The control group was treated with routine Azithromycin,and the observation group was treated with Montelukast Sodium on the basis of the control group.The clinical efficacy,symptoms and C-reactive protein level of the two groups were observed.Result:The total effective rate in the observation group(92.05%)was significantly higher than that of the control group(74.71%),the difference was statistically significant(P<0.05).The vanishing time of cough and rhonchus in the observation group were earlier than those in the control group,and the number of wheezing was less than that in the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in C-reactive protein levels between the two groups before treatment(P>0.05).After 1 week and 1 month of treatment,the observation group were lower than the control group,the differences were statistically significant(P<0.05).Conclusion:The early use of Montelukast Sodium in children with mycoplasma pneumoniae infection in the prevention of wheezing attack has a high feasibility,can improve the clinical efficacy of children,reduce the cough time and the number of wheezing,block the inflammatory response,is worthy of clinical promotion.
作者
黄俊生
HUANG Junsheng(Putian Children’s Hospital,Putian 351100,China)
出处
《中外医学研究》
2020年第20期166-168,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
孟鲁司特钠
肺炎支原体感染
喘息发作
C反应蛋白
Montelukast Sodium
Mycoplasma pneumoniae infection
Wheezing attack
C-reactive protein
